Eileen Tzng, Nathan Bayardo, Phillip C. Yang
{"title":"Current challenges surrounding exosome treatments","authors":"Eileen Tzng, Nathan Bayardo, Phillip C. Yang","doi":"10.1016/j.vesic.2023.100023","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73007,"journal":{"name":"Extracellular vesicle","volume":"2 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Extracellular vesicle","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2773041723000021","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
当前围绕外泌体治疗的挑战
心血管疾病是当今世界范围内死亡的主要原因,许多研究表明外泌体通过各种机制改善心肌损伤后的心功能。外泌体疗法作为一种针对潜在疾病过程的精准医学生物疗法具有巨大的潜力。然而,这种创新的方法可能面临一些挑战,如zeta电位、外泌体收集的标准化、生物制药监管,以及更重要的外泌体治疗的具体临床应用。这些问题将通过概括概括生物学上的合理性来解决;给药、给药和药代动力学;以及专注于作为分子货物的microRNA的可重复性和制造。
本文章由计算机程序翻译,如有差异,请以英文原文为准。